Table 2.

Conditioning regimens in groups of patients receiving transplants from MUDs and MMRDs

Donors	1 alkylator (Treo/Flu)*,†	2 alkylators (Treo/Flu + Mel or Thio)	2 alkylators (Treo/ Flu + Cy)	2 alkylators + G-CSF/plerixafor	ATGAM	Thymoglobulin	Alemtuzumab	No serotherapy	Rituximab
MUD, n = 75	21	44	2	8	8	62	3	2	56
MMRD, n = 23	4	8	2	9	2	21	0	0	20
n	25	52	4	17	10	83	3	2	76

^*1 alkylator: June 2012 to November 2014; 2 alkylators: from November 2014; 2 alkylators with G-CSF/plerixafor: from May 2016.

^†Total doses: Flu, fludarabine 150 mg/m²; Treo, treosulfan 42 g/m² (36 g/m² in patients younger than 1 year of age); Mel, melphalan 140 mg/m²; Thio, thiotepa 10 mg/kg; Cy, cyclophosphamide 40 to 120 mg/kg; G-CSF, 10 μg/kg/d for 5 days, plerixafor 240 μg/kg/d for 3 days; ATGAM (Pfizer) 90 mg/kg, thymoglobulin (Genzyme Europe B.V.) 5 mg/kg, alemtuzumab 1 mg/kg, rituximab 100-200 mg/m² on day −1.